Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E, Verschoor CP, Ma GW, Pawelec G. · 2020
Read Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. by Picard E, Verschoor CP, Ma GW, Pawelec G. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7068608.txt.
Introduction
Picard and co-authors relate immune landscapes to treatment response in colorectal cancer in Frontiers in Immunology. This cancer is deeply varied at the genetic level, and that variety decides whether immunotherapy can work. A small subset of tumours shows microsatellite instability, a sign of broken DNA mismatch repair. Those tumours carry many mutations, attract immune cells, and often respond strongly.
Checkpoint inhibitors targeting PD-1, nivolumab and pembrolizumab, are approved for patients with unstable, treatment-resistant metastatic disease. Most colorectal cancers are microsatellite-stable and respond poorly, though a few carry POLE mutations that load them with mutations and immune infiltrates too. The review connects each genetic subtype with its immune landscape, then asks why checkpoint blockade fails the majority despite immune infiltration predicting relapse and survival in early disease. Vaccine strategies and other routes to heat up cold tumours are also weighed.
Catalog record
| CREATOR | Picard E, Verschoor CP, Ma GW, Pawelec G. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 108 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |